Table 2

Mortality in DMARD and anti-TNF cohorts stratified by baseline RA-ILD

No baseline RA-ILDBaseline RA-ILDNo baseline RA-ILDBaseline RA-ILD
Patients (n)33966810350299
Total pyrs of follow-up8782152384231026
Median (IQR) follow-up per person (years)2.6 (1.7–3.6)2.1 (1.3–3.1)3.9 (2.7–4.9)3.8 (2.0–4.7)
 All-cause (n)1811463570
 All-cause mortality/1000 pyrs21 (18 to 24)92 (50 to 155)17 (15 to 18)68 (53 to 86)
 RA-ILD as cause, n (%)2 (1)1 (7)14 (2)15 (21)
 RA-ILD on cert, n (%)4 (2)2 (14)25 (4)24 (34)
MRR (unadjusted (95% CI))Referent0.74 (0.42 to 1.33)
MRR (adjusted for age and gender (95% CI))Referent1.26 (0.69 to 2.31)
MRR (adjusted for age and gender and calendar year (95% CI))Referent1.14 (0.58 to 2.26)
MRR (fully adjusted* (95% CI))
 Using patients with complete data setsReferent0.80 (0.34 to 1.87)
 Using imputed dataReferent0.81 (0.38 to 1.73)
  • * Confounders included in multivariable model (adjusting point estimate by >10%) included age, gender, calendar year of entry, disease duration, HAQ, DAS28, COPD/asthma, baseline steroid use and baseline methotrexate use. (RhF, EARA, diabetes and smoking not identified as confounders.)

  • COPD, chronic obstructive pulmonary disease; DAS28, disease activity score; DMARD, disease-modifying antirheumatic drug; EARA, extra-articular manifestations of rheumatoid arthritis; HAQ, Health Assessment Questionnaire; MRR, mortality rate ratio; pyrs, person years; RA-ILD, rheumatoid arthritis-associated interstitial lung disease; RhF, rheumatoid factor; TNF, tumour necrosis factor.